-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XXB-750 in Resistant Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XXB-750 in Resistant Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XXB-750 in Resistant Hypertension Drug Details: XXB-750 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roginolisib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roginolisib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roginolisib in Non-Small Cell Lung Cancer Drug Details: IOA-244 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roginolisib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roginolisib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roginolisib in Follicular Lymphoma Drug Details: IOA-244 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Urethral Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Urethral Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is an anti-neoplastic...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drugs In Development, 2023’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) - Drugs In Development, 2023’, provides an overview of the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) - Drugs In Development, 2023’, provides an overview of the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...